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Influence of Polymorphism within the Heme
Oxygenase-I Promoter on Overall Survival and
Transplantation-Related Mortality after Allogeneic
Stem Cell Transplantation
Armin Gerbitz,1,6 Patrick Hillemanns,2 Christoph Schmid,3 Andrea Wilke,2,6
Rajshri Jayaraman,4 Hans-Jochem Kolb,2,6 Gunther Eissner,5 Ernst Holler5
Aside from major and minor histocompatibility antigens, genetic polymorphisms of various donor and host
genes have been found to be risk factors for graft-versus-host disease and transplantation-related mortality
(TRM). The heme oxygenase I (HO-I) protein has been implicated in regulating inflammatory response and
has been described as a ‘‘protective gene’’ in solid organ transplantation. In humans, the promoter region
displays length polymorphism due to a variable number of GT repeats. Individuals exhibiting 29 or fewer
GT repeats express higher levels of HO-I on cellular stress compared with individuals with 30 or more
GT repeats. We retrospectively analyzed length polymorphisms of 92 donor–host pairs undergoing alloge-
neic stem cell transplantation. Our findings demonstrate that mainly donor polymorphism leading to high
expression of HO-1 (\30 GT repeats) on stress signals is associated with reduced overall survival, and
that TRM is significantly increased in this group. This reduction in survival was most prominent when unre-
lated donors were used. Polymorphisms of the recipient HO-1 genes did not influence posttransplantation
outcomes. We conclude that HO-1 polymorphism represents a new genetic risk factor for TRM and overall
survival.
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factorINTRODUCTION
Allogeneic stem cell transplantation is an impor-
tant therapeutic option for various malignant and non-
malignant diseases. To date, its use has been severely
limited because of transplantation-related complica-
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these is acute graft-versus-host disease (GVHD),
which continues to be the leading cause of early mor-
tality despite the development of various new, power-
ful immunosuppressive drugs. Aside from the major
histocompatibility complex (MHC), numerous genetic
non-MHC risk factors for acute GVHD have been
identified [1-4]. Most of these genetic differences
involve proinflammatory cytokines and proteins regu-
lating immune responses toward pathogens.
The pathophysiology of acute GVHD is believed
to involve three steps [5-7]. To allow the donor cells
to engraft, the host is preconditioned using total
body irradiation and/or chemotherapy. This treat-
ment results in the release of proinflammatory
cytokines from damaged tissue, activation of host
antigen-presenting cells [8], and severe impairment
of the intestinal mucosal barrier. In a second step, ac-
tivated host antigen-presenting cells stimulate mature
alloreactive donor T cells, which then mediate damage
in target tissues, such as the skin, liver, and gut. In
a third, parallel step, leakage of bacterial lipopolysac-
charides across the damaged mucosal barrier further
Biol Blood Marrow Transplant 14:1180-1189, 2008 1181Heme Oxygenase I and GVHDstimulates T cells and promotes the release of proin-
flammatory cytokines from antigen-presenting cells
[9,10].
In the pathophysiologic context of acute GVHD,
the enzyme heme oxygenase I (HO-1) may be in-
volved in several steps. HO-1 is the rate-limiting en-
zyme in the first step of heme degradation to
biliverdin, free iron, and carbon monoxide. It repre-
sents the inducible form of 2 isoforms of HO and is
expressed mainly in the spleen, where its substrate
heme is abundant because of erythrocyte sequestra-
tion. Aside from heme degradation, HO-1 also has
been attributed several regulatory functions in tissue
inflammation and protection against stress-induced
apoptosis. In fact, the protein was initially described
as heat shock protein 32 (Hsp32) [11,12] and appears
to play an important role in experimental solid organ
transplantation [13-16]. To date, few studies have ad-
dressed the function of HO-1 in the context of exper-
imental stem cell transplantation models. Woo et al.
[17] described the effect of inducing HO-1 in donor
cells before transplantation on reducing GVHD after
transplantation into haploidentical hosts. Recently,
our group [18] addressed the effect of HO-1 induc-
tion in the host before conditioning and showed that
GVHD was significantly reduced and survival im-
proved in animals with systemically induced HO-1
induction using cobalt protoporphyrine IX. We
hypothesized that HO-1 induction will lead to tissue
protection from total body irradiation–induced dam-
age and reduce cytokine release by host antigen-pre-
senting cells.
The human HO-I promoter contains a variable
(GT)n polymorphism in the 5´ region of the promoter.
GT repeats, the most frequent form of nucleotide re-
peats, are presumably negative gene regulators due to
the formation of Z-loops [19]. The number of GT re-
peats seems to be critical for the formation of Z-loops
and thus has an adverse influence on gene regulation in
many eukaryotic and prokaryotic genes. The distribu-
tion of the number of GT repeats within the HO-1
promoter permits the grouping into short (\ 25 GT
repeats), medium (25 to 30 GT repeats), and long
(.30 GT repeats) alleles. Short alleles are associated
with greater expression on cellular stress [20-22],
whereas long alleles are not. The exact mechanism of
this effect remains unclear, but numerous investigators
have suggested a strong role of HO-1 in oxidative
stress-mediated diseases and inflammation. Given the
experimental data and data from studies in humans,
we hypothesized that polymorphism of the HO-1
gene promoter would influence survival and the sever-
ity of GVHD as a non-MHC risk factor. We show
here that short and medium (25 to 30 GT repeats) do-
nor alleles had an adverse effect on overall survival
(OS), transplantation-related mortality (TRM) and
GVHD, and that this effect was most pronouncedwhen unrelated donors were used. These data suggest
that HO-1 may represent a new non-MHC risk factor
for TRM and OS.
MATERIALS AND METHODS
Patients
This study uses data from 92 patients admitted to
the University of Regensburg Hospital’s transplant
unit for allogeneic stem cell transplantation between
1998 and 2002. The conditioning regimen was either
standard intensity, using 8 to 12 Gy of total body
irradiation and high-dose cyclophosphamide (61 pa-
tients), or reduced-intensity cyclophosphamide (RIC)
using fludarabine, 1,3-bis(2chloroethyl)-1-nitrosurea
(BCNU), and melphalan (31 patients). Grafts were
from a matched related donor (MRD) in 42 patients
and from an unrelated donor (URD) in 50 patients. Pa-
tients receiving grafts from URDs received additional
in vivo T cell depletion by antithymocyte globulin
(ATG) or, in 1 case, Campath before transplantation.
Our sample did not include patients with disparate
HLA donor–host pairs. Immunosuppression com-
prised standard cyclosporine and methotrexate or cy-
closporine and mycophenolate-mofetil. The patients’
underlying disease and status at the time of transplan-
tation are shown in Table 1. Early/intermediate dis-
ease stage was defined as the first or second complete
remission (CR) of acute leukemia or a chronic or accel-
erated phase of chronic leukemia. The late disease
stage group comprised patients who did not achieve
CR or were beyond the second CR. The main indica-
tions for transplantation were acute leukemia, chronic
myelogenous leukemia, and non-Hodgkin lymphoma.
GVHDwas graded according to the Glucksberg crite-
ria [23] and major outcome variables, such as TRM
and OS, were updated monthly. The median patient
age was 45 years (range, 16 to 65 years).
DNA Sample Collection and Informed Consent
DNA samples used for this study were collected
from 108 consecutive patients who underwent trans-
plantation at Regensburg between 1998 and 2002.
Only 92 samples of donors and hosts (85.1%) were in-
cluded, because of missing samples from either donor
or host or poor-quality material. Samples were frozen
before transplantation and retrospectively analyzed for
HO-1 polymorphism. DNA from donor and host was
prepared from peripheral blood stem cells (PBSCs) us-
ing standard procedures and kits according to theman-
ufacturers’ protocols. Informed consent by donor and
host was obtained before stem cell collection for as-
sessment of genetic risk factors for GVHD, TRM,
and single nucleotide polymorphisms of inflammatory
proteins. The informed consent was approved by the
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(number 02/220).
Determination of Number of (GT)n Repeats
within the HO-1 Promoter Region
To determine the number of GT repeats within
the promoter region of theHO-1 gene, a sense primer,
5´-GAAGATCTTGCCAAGCAGTCAGCAGAG
GAT-3´, and a fluorescein-labeled antisense primer, 5´-
ACAGCTGATGCCCACTTTCT-3´, were used to
amplify 200 ng of genomic DNA derived from PBSCs.
The primers were obtained from Metabion (Mar-
tinsried, Germany). Optimal cycle conditions were
annealing at 60C for 30 seconds, followed by exten-
sion to 72C for 60 seconds over 48 cycles. To deter-
mine fragment length, the polymerase chain reaction
Table 1. Major Characteristics of Patients and Donors and
Transplantation Procedures
Patient characteristics
Age at transplantation, years
Mean 44.34
Median 45.00
Range 16-65
Sex
Male 40
Female 52
Cytomegalovirus status
Positive 41
Negative 51
Disease
Acute myelogenous leukemia/MDS 33
Acute lymphoblastic leukemia 5
Chronic myelogenous leukemia 19
OMF 7
Non-Hodgkin lymphoma 19
Chronic lymphocytic leukemia 1
MM 4
M. Hodgkin 2
SAA/PNH 1
Mamma-CA 1
Disease stage
Early/intermediate 54
Late 38
Conditioning regimen
Standard 61
RIC 31
T cell depletion
None 37
ATG/Campath/CD34 55
Donor characteristics
Age at transplantation, years
Mean 40.66
Median 39.00
Range 17-66
Sex
Male 55
Female 37
Cytomegalovirus status
Positive 32
Negative 60
Note. Standard conditioning regimens consisted of 8 to 12Gy total body
irradiation and high-dose cyclophosphamide. RIC was based mainly on
fludarabine, BCNU, and melphalan. ATG and Campath were given in
the course of pretransplantation conditioning.
MDS indicates myelodysplastic syndrome; SAA, severe aplastic anemia;
Mamma-CA, mamma carcinoma; RIC, reduced intensity conditioning;
ATG, antithymocyte globuline.product was loaded on a POP-4 matrix (Applied Bio-
systems, Darmstadt, Germany), and calculation of
fragment length was laser-based through an automated
sequencer through comparison to sequenced alleles of
different lengths. The range of error was\ 0.5 bp.
HO-1 (GT)n Polymorphism Grouping
The number of (GT)n repeats varied from 16 to 38.
We followed Yamada et al. [20] in our choice of classifi-
cationbydividing the alleles into3groups: class S alleles,
with\25GT repeats; classM alleles, with 25 to 29GT
repeats; and class L alleles, with 3 30 GT repeats. This
classification schemeaffords 6possible genotypeswithin
the donor and host population: S/S, S/M, M/M, M/L,
LL, and S/L. Based on their functional data, Yamada
et al. [20] further aggregated these donor–host permuta-
tions with respect to L class alleles. Group I contains all
individuals with no class L alleles (ie, only M and S
alleles), and group II contains all individuals with 1 or
2 classL alleles.Thus, eachpatient/donorpairhas 4pos-
sible permutations: donor group I/host group I, donor
group II/host group I, donor group I/host group II,
and donor groupII/host group II. We followed Yama-
da’s classification, labeling his ‘‘group I’’ HO-1high and
his ‘‘group II’’ HO-1low. In a further categorization,
we grouped patients in which neither the donor nor
the host has any class L allele asHO-1high, with all other
permutations relegated to the second group.
Clinical and Statistical Analysis
For this study, SPSS statistical analysis software,
version 14.0 (SPSS Inc, Chicago, IL) was used. Major
outcome variables, including OS, TRM, overall acute
GVHD, and gastrointestinal GVHD were analyzed
in relation to host and donor both individually and in
groups, as described earlier. The time to clinical event
was calculated from the date of transplantation. For
OS and disease-free survival (DFS), the Kaplan-Meier
methodology was used. For overall acute GVHD and
gastrointestinal GVHD, events occurring until day
100 were included. Deaths from relapse were calcu-
lated as competing risks where indicated.
RESULTS
Allele Frequency of GT Repeats among Donor
and Host Groups
The number of (GT)n repeats among the individ-
uals in our study ranged from 15 to 38. Because each
individual carries 2 alleles, 184 alleles were analyzed
for both donors and hosts. The histograms shown in
Figure 1 show the distribution of number of GT re-
peats for the study population. The mode of the distri-
bution among both donors and recipients was 29, with
additional peaks at 23 and 30. The mean of the host
Biol Blood Marrow Transplant 14:1180-1189, 2008 1183Heme Oxygenase I and GVHDand donor distributions was 27.3 (6 3.7) and 27.7
(6 3.8), respectively. Using a Kolmogorov-Smirnov
test, we were unable to reject the null hypothesis that
the donor and host allele distributions are identical
(P5 .574; Kolmogorov-Smirnov z5 0.782). These re-
sults are in line with data from cohorts in Japan and
Europe published previously [20,24,25].
Table 2 summarizes various patient and treatment
characteristics, disaggregated by group. In column 1,
patients are grouped into 2 categories: those with a do-
nor with no L-allele ($ 30 GT repeats), the HO-1high
expressers, and those with 1 or 2 L-alleles, the HO-
1low expressers. The first 3 columns correspond to
groups disaggregated by donor HO-I expression,
whereas the last 3 columns correspond to patient
HO-I expression. As the P values indicate, there is no
significant difference in outcome covariates across
these groups. Only in the case of sex and donor vari-
ables in the donor grouping (Table 2, donor column)
is a trend toward significance seen, with males more
likely to belong to the HO-1high group (P 5 .05) and
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Figure 1. Frequency of number of (GT)n repeats. Each individual car-
ries 2 alleles; thus, 184 alleles were analyzed for both the donor and
host groups. The number of (GT)n repeats was analyzed as described
for donors and recipients. The average number of (GT)n repeats was
27.7 6 3.8 in the donor group and 27.3 6 3.6 in the recipient group .
The median was 29 in both groups, ranging from 15 to 38 in the donor
group and from 21 to 38 in the host group. Similarity between both
groups was determined using the Kolmogorov-Smirnov test (P 5 .574;
z 5 0.782).matched URDs more likely to belong to the HO-1low
group (P 5 .07). Because being male is considered
a risk factor for TRM and GVHD, this overrepresenta-
tion of males could be a potential source of bias toward
worse outcomes in the group of HO-1high donors. In
contrast, the HO-1high donor group contained more
matched related sibling donors, which may be a source
of downward bias in GVHD development and TRM.
In general, the covariates do not appear to be systemat-
ically correlated with the HO-1 grouping.
Overall Survival, Transplantation-Related
Mortality, and Graft-versus-Host Disease
Table 3 describes the proportion of patients in
each of the groups with respect to various posttrans-
plantation outcomes. As the ‘‘donor’’ column indi-
cates, patients receiving grafts from donors
displaying an HO-1high polymorphism had a signifi-
cantly reduced OS (P 5 .023) and DFS (P 5 .018), as
well as a trend toward significance with respect to
higher TRM (P 5 .057). In contrast, polymorphism
of the host had no significant influence on any of these
outcomes. Only in the case of transplantation-related
complications in the form of idiopathic pneumonia
syndrome (IPS)/acute respiratory distress syndrome
(ARDS)/pneumonia was there a trend toward signifi-
cance, with HO-1high polymorphism in the host asso-
ciated with worse outcomes (P 5 .066). Interestingly,
a combination of HO-1high expressing donors with
HO-1high expressing hosts indicates that the absence
of an L-allele in both donor and host is even more
closely associated with worse transplantation-related
outcomes in all but one of the outcomes considered
here. Patients exhibited significantly higher TRM
(P 5 .006), gut GVHD (P 5 .052), and acute severe
GVHD (P 5 .008) and lower DFS (P 5 .002) and
OS (P 5 .011) when both they and their hosts had
HO-1high polymorphism (data not shown).
Figure 2 scrutinizes the survival data for donor and
host HO-1 polymorphism in more detail. It examines
OS between groups disaggregated by MRDs (A) and
matched URDs (B). Among the patients with MRDs,
OS did not differ significantly based on this HO-I
grouping (71.3% vs 55.1%). In contrast, OS in patients
receiving grafts from an HO-1high URD was consider-
ably lower than that in their HO-1low counterparts
(41.7% vs 81.8%; P 5 .015; log-rank test). This sug-
gests that URD polymorphism influences OS. The
same cannot be said of recipient HO-1 polymorphism
receiving grafts from an URD; although patients with
HO-1high polymorphism had lower OS than their
HO-1low counterparts (73.7% vs 54.8%), this differ-
ence was not statistically significant (data not shown).
To support this finding, we also analyzed OS compar-
ing HO-1high MRDs and URDs and HO-1low MRDs
and URDs (data not shown). In neither case was any
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Donor Host
HO-1high HO-1low P HO-1
high HO-1low P
Patient sex
Female 20 20 .05 24 16 .57
Male 37 15 31 21
Recipient age
< 40 years 20 12 .56 21 11 .27
> 40 years 37 23 34 26
Disease stage
Early/intermediate 32 22 .34 31 23 .37
Advanced 25 13 24 14
Donor
Matched sibling 30 12 .07 24 18 .39
Matched unrelated 27 23 31 19
Disease
Acute leukemia 20 18 .40 22 16 .86
Chronic myelogenous leukemia, OMF, SAA 19 8 16 11
Non-Hodgkin lymphoma, Hodgkin lymphoma 17 9 16 10
Mamma carcinoma 1 0 1 0
Sex mismatch
Female into male 10 6 .60 30 7 .48
Others 47 29 46 9
T cell depletion
ATG, Campath 31 24 .13 35 20 .24
No 26 11 20 17
Stem cell source
Bone marrow 19 7 .13 15 11 0.49
PBSC 38 28 40 26
Conditioning
Standard 35 26 .15 39 22 0.18
RIC 22 9 16 15
Note. Donor and host were grouped according to number of (GT)n repeats, as described in Materials and Methods. There was a trend toward signif-
icance with more male patients in the HO-1high donor group (P 5 05) and more transplantations from matched siblings in the HO-1high donor group
(P 5 07).
OMF indicates osteomyelofibrosis; SAA, severe aplastic pneumonia.statistically significant difference observed (HO-1high
MRD vs URD, P 5 .167; HO-1low MRD vs URD, P
5 .705). When HO-1 polymorphism groups were dis-
aggregated according to the use of ATG as in vivo T
cell depletion, we observed similar results with respect
to donor polymorphism, becausemost ATG recipients
are in the URD group (OS: no ATG/Campath HO-
1high, 64.9% vs HO-1low, 72.7%, P 5 .593; ATG/
Campath HO-1high, 48.4% vs HO-1low, 83.3%, P 5
.012; TRM: no ATG/Campath HO-1high, 20.0% vs
HO-1low, 9.1%, P 5 .463; ATG/Campath HO-1
high,
35.5% vs HO-1low, 12.5%, P 5 .041).
Table 3. Transplantation-Related Mortality, Graft-versus-
Host Disease, Disease-Free Survival, and Overall Survival
Donor Host
HO-1high HO-1low P HO-1
high HO-1low P
TRM 28.1 11.4 .057 25.5 16.2 .318
Gut GVHD $ 3 17.5 5.7 .111 16.4 8.1 .349
GVHD $ 3 28.1 14.3 .123 29.1 13.5 .127
IPS, ARDS,
pneumonia
23.8 33.3 1.000 37.5 0.0 .066
DFS 45.6 71.4 .018 49.1 64.9 .19
OS 54.4 80.0 .023 60.0 70.3 .61
Note. All values are given as percentages. Significance was calculated
using the c2 test for acute GVHD, gut GVHD, and IPS; for OS, TRM
and DFS was calculated using the log-rank test.Figure 3 shows the incidence of TRM (A) and se-
vere acute GVHD (B) using URDs only. As depicted,
TRM was increased significantly when HO-1high ex-
pressing URDs were used (48.5% vs. 14.03%; P 5
.030; log-rank test). Similarly, the incidence of severe
acute GVHD in this group also was higher, but the dif-
ference did not reach statistical significance at the 5%
level (37.7% vs. 18.5%; P\ .08; log-rank test).
Influence of Conditioning and Disease-Free
Survival
Based on our experimental data, we can conclude
that HO-1 expression can confer protection against
irradiation-induced damage and consequent GVHD.
Given the regulatory potential of HO-1 with respect
to apoptosis and anti-inflammatory properties, we an-
alyzed the impact of conditioning regimens on out-
comes in different polymorphism subgroups. Our
results pertaining to OS and TRM given earlier were
not affected by the conditioning regimen applied; nei-
ther standard nor reduced intensity conditioning influ-
enced the differences seen within the donor HO-1
polymorphism. Similar results also were obtained
with respect to DFS. As shown in Table 3, HO-1high
donor polymorphism was associated with reduced
DFS, which was somewhat surprising, because more
Biol Blood Marrow Transplant 14:1180-1189, 2008 1185Heme Oxygenase I and GVHDsevere GVHD also was seen in that same group. Com-
paring DFS in the MRD and URD groups revealed no
difference in outcomes (57.1% in MRD vs 54% in
URD; P 5 .541); however, HO-1 polymorphism had
an effect on DFS in the URD group but did not in
theMRD group. In the former group, HO-1high donor
polymorphism negatively influenced DFS (HO-1high,
46.3% vs HO-1low, 74.6%; P 5 .120). Host polymor-
phism had no influence on DFS (HO-1high 56.2% vs
HO-1low 71.1%; P 5 .521). As shown in Figure 4A,
when HO-1 polymorphism of donor and host were
grouped such that HO-1high expressing donors and re-
cipients formed a single group against all other permu-
tations containing at least 1 HO-1low allele, again no
significant difference in DFS was seen when MRDs
were used; however, in the URD group, DFS was sig-
nificantly reduced (HO-1high donor and host, 32.1% vs
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Figure 2. OS of donor HO-1high donors (solid line) and HO-1low do-
nors (dotted line). A, OS using MRDs (HO-1high, 71.3% vs HO-1low,
55.1%; P5 not significant; log-rank test). The number of events/number
of patients was 11/29 for HO-1high and 3/11 for HO-1low. The median
GT(n) repeats was 29, and the average was 27.3 6 4.3. B, OS using
matched URDs (HO-1high 41.7% vs HO-1low 81.8%; P 5 .015; log-rank
test). The number of events/number of patients was 14/26 for HO-
1high and 4/22 for HO-1low. The median GT(n) repeats was 29, and
the average was 27.4 6 3.4.all other permutations, 76.1%; P 5 .002). Almost su-
perimposable results were obtained when data were
analyzed according to the use of ATG in the condi-
tioning regimen, because with few exceptions, only
patients with a matched URD received ATG for
conditioning.
Multivariate Analysis of Risk Factors Associated
with Transplantation-Related Mortality and
Overall Survival
Table 4 presents results from our Cox regression
analyzing competing risk factors for OS and TRM
for URDs. T cell depletion by ATG or Campath was
not included as a risk factor, because in almost all cases,
patients receiving grafts from URDs received ATG,
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Figure 3. TRM and acute severe GVHD. HO-1high donors (solid line)
compared with HO-1low donors (dotted line) using only URDs. A,
TRM was increased in the group of unrelated HO-1high donors (48.5%
vs 14.3%; P 5 .030; log-rank test). The number of events/number of pa-
tients was 11/26 for HO-1high and 3/22 for HO-1low 3/22. B, Cumulative
incidence of acute severe GVHD (grade 3-4) was increased when HO-
1high URDs were used (37.7% vs 18.5%; P\.08; log-rank test). The num-
ber of events/number of patients was 8/26 for HO-1high and 4/22 for
HO-1low.
1186 Biol Blood Marrow Transplant 14:1180-1189, 2008A. Gerbitz et al.and in 1 case, Campath, during the conditioning regi-
men (MRD, 6 of 42 vs URD, 49 of 50; P\ .001; c2
test). The HO-1 polymorphism grouping in the last
row pertains to that of the URD. As the P values for
OS indicate, only the disease stage and donor HO-1
polymorphism had a significant impact on OS. Pa-
tients with advanced disease are 3.01 times more likely
to die than those at an early or intermediate stage (P5
.021). HO-1high donor polymorphism also verged on
significance for both OS (P 5 .029) and TRM (P 5
.026); indeed, in the case of TRM, HO-1high donor
polymorphism was the only significant risk factor. In-
terestingly, when we ran an analogous Cox regression,
substituting HO-1high host polymorphism for
HO-1high donor polymorphism, we found that this
variable had no significant effect on either OS (P 5
.87) or TRM (P5 .62) (data not shown). Because after
transplantation, 2 possible genotype groups are com-
bined, we also included in our Cox regression model
the genotype of the recipient as a competing risk factor
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Figure 4. DFS of donor/recipient HO-1high groups (solid line) com-
pared with all other permutations of donor and host HO-1 polymor-
phisms containing at least 1 HO-1low allele of donor or recipient
(dotted line). A, DFS using MRDs. No significant difference was
observed (62.6 vs. 33.4, P 5 .582) B, DFS using URDs (HO-1high donor
and host, 32.1% vs all other permutations, 76.1%; P 5 .002).for URDs. The qualitative results were unchanged.
For TRM (P 5 .043; hazard ratio [HR] 5 3.73; 95%
confidence interval [CI] 5 1.04 to 13.4), donor geno-
type remained the only significant risk factor. For
OS, HO-1high donor polymorphism was significant
(P 5 .045; HR 5 3.12; 95% CI 5 1.02 to 9.53), and,
as expected, disease stage remained a significant risk
factor (P5 .027’ HR5 3.02, 95% CI5 1.13 to 8.06).
To prevent the introduction of bias by choosing
matched URD transplants only for the Cox regression
analysis and neglecting the interaction between trans-
plant type and genotype, we also analyzed the influ-
ence of donor and host genotype in the entire cohort
(data not shown). Similar to the foregoing results, do-
nor polymorphism verged on significance as a risk fac-
tor for OS (P 5 .064; HR 5 2.21; 95% CI 5 0.95 to
5.11) as well as for TRM (P 5 .037; HR 5 3.25;
95% CI 5 1.08 to 9.83).
DISCUSSION
Over the last decade, theHO-I system has emerged
as a major factor in controlling local inflammation and
inducing tolerance [26,27]. So far, the effects of this
protein have been reported in experimental systems
with regard to solid organ transplantation [28,29]. In
addition, there have been numerous reports on the in-
volvement of polymorphisms within the promoter
Table 4. Multivariate Risk Factor Analysis for OS and TRM
According to HO-1high Donor Polymorphism
n
Number
of Events HR 95% CI P
OS
Age
# 40 years 24 10 1.00 0.38–2.34 .904
> 40 years 26 9 0.95
Disease stage
Early/intermediate 28 6 1.00 1.13–8.05 .021
Advanced 22 13 3.01
Stem cell source
Bone marrow 15 5 1.00 0.33–2.89 .967
PBSC 35 14 0.97
HO-1 polymorphism
Donor HO-1low 23 4 1.00 1.02–9.52 .029
Donor HO-1high 27 15 3.12
TRM
Age
# 40 years 24 9 1.00 0.17–1.57 .239
> 40 years 26 5 0.53
Disease stage
Early/intermediate 28 6 1.00 0.60–5.34 .284
Advanced 22 8 1.80
Stem cell source
Bone marrow 15 4 1.00 0.26–3.14 .881
PBSC 35 10 0.90
HO-1 polymorphism
Donor HO-1low 23 4 1.00 1.04–13.4 .026
Donor HO-1high 27 10 3.73
Note. Age, disease stage, stem cell source, and HO-1 polymorphism of
donor and host were included in the analysis as relevant risk factors for
OS and TRM. Only patients with unrelated donors were included, and
thus all patients underwent T cell depletion by ATG or Campath during
conditioning.
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the pulmonary and vascular systems [20,30]. To the
best of our knowledge, this is the first report analyzing
the impact of HO-1 polymorphisms in an allogeneic
stem cell transplantation setting.
Using retrospective data on 92 patient–donor
pairs, we find that length polymorphism in the donor
but not in the host alone significantly influence such
posttransplantation outcomes as OS andTRM. In par-
ticular, patients in our data with medium and short al-
leles [\ 30(GT)n repeats] in the donor alone typically
have significantly worse outcomes.
The number of (GT)n repeats within the promoter
region influences the expression levels of HO-1 on cel-
lular stress. Short alleles [\ 30 (GT)n repeats] are as-
sociated with the ability to mount a quantitatively
higher HO-1 response. Our finding is thus at odds
with a number of other studies that ascribe a protective
role for high HO-1 expression (reviewed by Exner
et al. [31]). Studies in humans as well as experimental
studies in solid organ transplantation have suggested
that expression of HO-1 in specific tissues is generally
associated with prolonged graft survival, reduced leu-
kocyte infiltration, and, more recently, even with toler-
ance [28,29,32-34]. Results based on our retrospective
data also appear to run counter to those based on ex-
perimental data from our group and others [17,18].
In an earlier experimental study, we showed that in-
duction of HO-1 in recipient mice using protoporphy-
rins as an HO-1 inductor is associated with improved
OS, reduced GVHD and reduction of the release of
proinflammatory cytokines. Obtaining similar results
by administering protoporphyrins to the donor, Woo
et al. [17] argued that donor cells rather than the recip-
ient are influenced by the induction of HO-1. Due to
the antiapoptotic effects of HO-1, we hypothesized
in our experimental study that induction of HO-1 be-
fore conditioning would protect the host and thereby
reduce GVHD. This hypothesis was confirmed by his-
tology and reduced lipopolysaccharide transfer across
the damaged gut mucosa. What the data presented
here suggest, however, is that the host’s ability to
mount an HO-1 response has little or no bearing on
posttransplantation outcomes. One possible explana-
tion for this discrepancy is that we do not yet know
whether the experimental data on generally high
HO-1 expression (vs no expression in untreated
mice) within parenchyma reflects the differences in ex-
pression seen in humans due to the variable number of
(GT)n repeats. In addition, HO-1 expression in donor
cells is associated with improved survival [17], in con-
trast to the results in this study, where HO-1high
expressing donors contribute to significantly to worse
outcomes.
At this stage, it is worth making a number of qual-
ifications regarding our findings. First, our data are
retrospective, and the sample size is limited. Second,although we do take well-established risk factors relat-
ing to posttransplantation outcomes into account, the
specification of HO-1 in the empirical model, al-
though based on data from other studies, remains
speculative; for example, given the distribution of
(GT)n repeats (Figure 1), our results are clearly sensi-
tive to the specification of the threshold number of
(GT)n repeats for HO-1low or HO-1
high expression.
Therefore, we conducted some robustness checks,
varying the threshold above and below the 30 GT re-
peats used by Yamada et al. [20] and in the present
study. For all thresholds above 30 and all those below
30, there was no statistical difference in OS and TRM
between HO-1low or HO-1
high under the new catego-
rization. In essence, by shifting the threshold down, we
moved SS, SM, or MM alleles (HO-1high) into the L
allele (HO-1low) group. This worsened the outcomes
in this group. The same logic held in reverse when
we moved thresholds upward. Given that our distribu-
tion of (GT)n repeats is in line with published data,
these robustness checks support the use of this thresh-
old. In addition, the grouping of our data into HO-
1high and HO-1low was necessitated by the fact that
each patient has 2 alleles. Both alleles have been shown
to play a role in HO-1 expression, but the question re-
mains as to which length polymorphism is driving the
divergent outcomes in the 2 groups. To examine this,
we excluded mixed genotypes of the donors (ML and
SL) from the analysis and compared only HO-1high
groups (SS, SM, and MM) with HO-1low groups
(LL). Doing so led to an evenmore pronounced differ-
ence in outcomes; Kaplan-Meyer estimates indicated
an OS of 100% in the HO-1low LL group and 45.8%
in the HO-1high group (P 5 .012, data not shown)
and corresponding TRMs of 0% and 34.4% (P 5
.047; data not shown). This suggests that the presence
of an extra L allele may play an important protective
role posttransplantation.
One striking observation in our study was the ef-
fect of URD HO-1high polymorphism on OS and
TRM. The clear difference between the MRD and
URD groups in our cohort is the use of in vivo T
cell depletion before transplantation by ATG or Cam-
path. When MRDs and URDs were included in the
multivariate analysis, T cell depletion per se had no
impact on the outcome (data not shown). The link be-
tween T cell function and its modulation by HO-1 ex-
pression (or vice versa) within parenchyma or in
professional antigen-presenting cells is poorly under-
stood. There is increasing data on how Tregs manip-
ulate the parenchymal environment and thereby
down-modulate inflammatory responses [35,36]. One
proposed model describes the induction of inducible
nitric oxide synthase and indolamine-2-3-dioxygenase
by interferon (IFN)-g derived from activated Tregs
and subsequent release of 3-hydroxyanthranilic acid,
which is a strong inducer of HO-1 [37]. Activation
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then counterbalances the excessive release of proin-
flammatory cytokines and provides a survival signal
for target tissue cells. The depletion of Tregs by
ATG and Campath may lead to a missing anti-inflam-
matory stimulus and an interrupted negative feedback
loop. One interpretation would be that individuals
with HO-1high polymorphism are more dependent
on this genetically defined counterregulation. This
hypothesis also would explain why the combination
of donor and host HO-1high polymorphisms worsens
outcomes after allogeneic stem cell transplantation.
In this situation, both sides are unable to properly
balance their response.
The depletion of T cells through ATG or Cam-
path is not limited to Tregs and depletion of part of
the donor, and most of the host T cell compartment
mainly affects the release of IFN-g during the peri-
transplantation period. The function of this cytokine
in the context of allogeneic stem cell transplantation
remains under debate, but pleiotropic function in exac-
erbating GVHD and preventing GVHD has been re-
ported in experimental mouse models (as reviewed
by Yang et al. [38]). Several experimental models
have demonstrated that donor-derived IFN-g is neces-
sary for reduction of acute GVHD [39]. In addition,
polymorphisms within the human IFN-g gene leading
to lower expression (IFN-g intron1 3/3 genotype) are
associated with the development of severe GVHD
[4,40]. So far, few studies have revealed a link between
HO-1 expression and IFN-g release [41-43], but those
authors suggested that the protective effects of IFN-g
are associated with up-regulation of HO-1 in the
parenchyma, leading to reduced immunogenicity. In
line with these findings is the observation that in
humans, unlike mice, IFN-g represses HO-1 up-regu-
lation [44]. Depletion of host T cells and parts of donor
T cells using ATG before conditioning results in
reduced IFN-g release and reduced HO-1 induction.
Donors and hosts with HO-1high polymorphism are
presumably more dependent on up-regulation of HO-1
as a means of inflammatory counteraction and this may
explain the increased TRM in this case.
Using ATG in the conditioning regimen had an in-
fluence on the relapse rates when the data were disag-
gregated by HO-1 polymorphism. Although we
observed no difference in DFS according to MRD or
URD overall, the use of ATG in the URD group led
to deleterious DFS survival, when both donor
and recipient displayed HO-1high polymorphism
(Figure 4B). This corroborates findings in recent pub-
lications suggesting that the expression of HO-1 rep-
resents a survival and resistance factor for leukemic
cells [21,45-47]. Polymorphism and different levels
of expression also may play a role in sufficient leukemia
rejection, because the largest number of severe acute
GVHD was observed in this group of patients.In summary, the data presented in this study de-
scribe a potentially novel non-MHC risk factor that
significantly impacts OS, TRM, and acute and severe
GVHD after allogeneic stem cell transplantation.
The influence of HO-1 on the regulation of the im-
mune system is not fully understood and requires fur-
ther experimental support. The evidence presented
here on the basis of a retrospective study needs to be
confirmed by a prospective investigation.
ACKNOWLEDGMENTS
This work was supported by grants from the
Friedrich-Bauer Foundation and the Wilhelm-Sander
Foundation.The authors declare no conflict of interest.
REFERENCES
1. Barrett AJ, Rezvani K, Solomon S, et al. New developments in
allotransplant immunology. Hematology Am Soc Hematol Educ
Program. 2003;350-371.
2. Dickinson AM, Cavet J, Cullup H, et al. Predicting outcome in
hematological stem cell transplantation. Arch Immunol Ther Exp
(Warsz). 2002;50:371-378.
3. Dickinson AM,Middleton PG. Beyond theHLA typing age: ge-
netic polymorphisms predicting transplant outcome. Blood Rev.
2005;19:333-340.
4. Dickinson AM, Middleton PG, Rocha V, et al. Genetic poly-
morphisms predicting the outcome of bone marrow transplants.
Br J Haematol. 2004;127:479-490.
5. Hill G, Crawford J, Cooke K, et al. Total body irradiation and
acute graft-versus-host disease: the role of gastrointestinal dam-
age and inflammatory cytokines. Blood. 1997;90:3204-3213.
6. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as
a target organ of acute graft-versus-host disease: rationale for the
use of cytokine shields in allogeneic bone marrow transplanta-
tion. Blood. 2000;95:2754-2759.
7. Ferrara JL, Cooke KR, Teshima T. The pathophysiology of
acute graft-versus-host disease. Int J Hematol. 2003;78:181-187.
8. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of
graft-versus-host disease by inactivation of host antigen- pre-
senting cells. Science. 1999;285:412-415.
9. Cooke KR, Gerbitz A, Crawford JM, et al. LPS antagonism re-
duces graft-versus-host disease and preserves graft-versus-leuke-
mia activity after experimental bone marrow transplantation.
J Clin Invest. 2001;107:1581-1589.
10. Teshima T, Ordemann R, Reddy P, et al. Acute graft-versus-
host disease does not require alloantigen expression on host
epithelium. Nat Med. 2002;8:575-581.
11. Maines MD, Panahian N. The heme oxygenase system and cel-
lular defense mechanisms: do HO-1 and HO-2 have different
functions? Adv Exp Med Biol. 2001;502:249-272.
12. MainesMD.Heme oxygenase: function, multiplicity, regulatory
mechanisms, and clinical applications. FASEB J. 1988;2:
2557-2568.
13. Bach F, Ferran C, Hechenleitner P, et al. Accommodation of
vascularized xenografts: expression of protective genes by donor
endothelial cells in a host Th2 cytokine environment. Nat Med.
1997;3:196-204.
14. Otterbein LE, Bach FH, Alam J, et al. Carbon monoxide has
anti-inflammatory effects involving the mitogen-activated pro-
tein kinase pathway. Nat Med. 2000;6:422-428.
15. Soares MP, Brouard S, Smith RN, et al. Heme oxygenase-1,
a protective gene that prevents the rejection of transplanted
organs. Immunol Rev. 2001;184:275-285.
Biol Blood Marrow Transplant 14:1180-1189, 2008 1189Heme Oxygenase I and GVHD16. Wang N, Lee JM, Soares MP, et al. TH2 cytokines regulate
gene expression and proinflammatory responses in xenografts.
Transplant Proc. 2001;33:776-777.
17. Woo J, Iyer S,Mori N, et al. Alleviation of graft-versus-host dis-
ease after conditioning with cobalt- protoporphyrin, an inducer
of heme oxygenase-1. Transplantation. 2000;69:623-633.
18. Gerbitz A, Ewing P, Wilke A, et al. Induction of heme oxygen-
ase-1 before conditioning results in improved survival and re-
duced graft-versus-host disease after experimental allogeneic
bone marrow transplantation. Biol Blood Marrow Transplant.
2004;10:461-472.
19. Naylor LH, Clark EM. d(TG)n.d(CA)n sequences upstream of
the rat prolactin gene form Z-DNA and inhibit gene transcrip-
tion. Nucleic Acids Res. 1990;18:1595-1601.
20. YamadaN, YamayaM,Okinaga S, et al.Microsatellite polymor-
phism in the heme oxygenase-1 gene promoter is associated with
susceptibility to emphysema. Am J Hum Genet. 2000;66:
187-195.
21. Hirai H, Kubo H, Yamaya M, et al. Microsatellite polymor-
phism in heme oxygenase-1 gene promoter is associated with
susceptibility to oxidant-induced apoptosis in lymphoblastoid
cell lines. Blood. 2003;102:1619-1621.
22. YamayaM, Nakayama K, Ebihara S, et al. Relationship between
microsatellite polymorphism in the haem oxygenase-1 gene pro-
moter and longevity of the normal Japanese population. J Med
Genet. 2003;40:146-148.
23. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of
graft-versus-host disease in human recipients of marrow from
HL-A–matched sibling donors. Transplantation. 1974;18:
295-304.
24. Kimpara T, Takeda A, Watanabe K, et al. Microsatellite poly-
morphism in the human heme oxygenase-1 gene promoter and
its application in association studies with Alzheimer and Parkin-
son disease. Hum Genet. 1997;100:145-147.
25. Guenegou A, Leynaert B, Benessiano J, et al. Association of lung
function decline with the heme oxygenase-1 gene promoter mi-
crosatellite polymorphism in a general population sample: re-
sults from the European Community Respiratory Health
Survey (ECRHS), France. J Med Genet. 2006;43:e43.
26. Bach FH. Heme oxygenase-1 and transplantation tolerance.
Hum Immunol. 2006;67:430-432.
27. Bach FH. Heme oxygenase-1 as a protective gene. Wien Klin
Wochenschr. 2002;114(Suppl 4):1-3.
28. Martins PN, Kessler H, Jurisch A, et al. Induction of heme oxy-
genase-1 in the donor reduces graft immunogenicity. Transplant
Proc. 2005;37:384-386.
29. Tullius SG, Nieminen-Kelha M, Reutzel-Selke A, et al. Im-
provement of long-term function in renal allografts from ‘‘mar-
ginal donors’’ following the induction of heme oxygenase-1.
Transplant Proc. 2001;33:1160-1161.
30. Schillinger M, Exner M, Minar E, et al. Heme oxygenase-1 ge-
notype and restenosis after balloon angioplasty: a novel vascular
protective factor. J Am Coll Cardiol. 2004;43:950-957.
31. Exner M, Minar E, Wagner O, et al. The role of heme oxygen-
ase-1 promoter polymorphisms in human disease. Free Radic Biol
Med. 2004;37:1097-1104.32. Exner M, Bohmig GA, Schillinger M, et al. Donor heme oxy-
genase-1 genotype is associated with renal allograft function.
Transplantation. 2004;77:538-542.
33. Katori M, Busuttil RW, Kupiec-Weglinski JW. Heme oxygen-
ase-1 system in organ transplantation. Transplantation. 2002;74:
905-912.
34. Yamashita K, Ollinger R, McDaid J, et al. Heme oxygenase-1 is
essential for and promotes tolerance to transplanted organs. FA-
SEB J. 2006;20:776-778.
35. Zenclussen AC, Gerlof K, Zenclussen ML, et al. Regulatory T
cells induce a privileged tolerant microenvironment at the fe-
tal–maternal interface. Eur J Immunol. 2006;36:82-94.
36. Wood KJ, Sawitzki B. Interferon gamma: a crucial role in the
function of induced regulatory T cells in vivo. Trends Immunol.
2006;27:183-187.
37. Oh GS, Pae HO, Choi BM, et al. 3-Hydroxyanthranilic acid,
one of metabolites of tryptophan via indoleamine 2,3-dioxyge-
nase pathway, suppresses inducible nitric oxide synthase expres-
sion by enhancing heme oxygenase-1 expression. BiochemBiophys
Res Commun. 2004;320:1156-1162.
38. Yang YG,WangH, AsavaroengchaiW, et al. Role of interferon-
gamma inGVHD andGVL.Cell Mol Immunol. 2005;2:323-329.
39. Burman AC, Banovic T, Kuns RD, et al. IFNgamma differen-
tially controls the development of idiopathic pneumonia syn-
drome and GVHD of the gastrointestinal tract. Blood. 2007;
110:1064-1072.
40. Cavet J, Dickinson AM, Norden J, et al. Interferon-gamma and
interleukin-6 gene polymorphisms associate with graft-versus-
host disease in HLA-matched sibling bone marrow transplanta-
tion. Blood. 2001;98:1594-1600.
41. Reeve VE, Domanski D. Refractoriness of UVA-induced pro-
tection from photoimmunosuppression correlates with heme
oxygenase response to repeatedUVA exposure. Photochem Photo-
biol. 2002;76:401-405.
42. Reeve VE, Domanski D. Immunoprotective haem oxygenase in-
duction by ultraviolet A (320-400 nm) radiation in the mouse is
inhibited in interferon-gamma null mice. Br J Dermatol. 2003;
148:1189-1193.
43. Tsuchihashi S, Zhai Y, Fondevila C, et al. HO-1 upregulation
suppresses type 1 IFN pathway in hepatic ischemia/reperfusion
injury. Transplant Proc. 2005;37:1677-1678.
44. Sikorski EM, Hock T, Hill-Kapturczak N, et al. The story so
far: molecular regulation of the heme oxygenase-1 gene in renal
injury. Am J Physiol Renal Physiol. 2004;286:F425-F441.
45. Mayerhofer M, Gleixner KV, Mayerhofer J, et al. Targeting of
heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in
leukemic cells in chronic myeloid leukemia: a novel approach
to overcome resistance against imatinib. Blood. 2008;111:
2200-2210.
46. Mayerhofer M, Florian S, Krauth MT, et al. Identification of
heme oxygenase-1 as a novel BCR/ABL-dependent survival
factor in chronic myeloid leukemia. Cancer Res. 2004;64:
3148-3154.
47. Rushworth SA, MacEwan DJ. HO-1 underlies resistance of
AML cells to TNF-induced apoptosis. Blood. 2008;111:
3793-3801.
